Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 16/20 | 0.55 |
| ▸ | KDM5B | Q9UGL1 | 6/20 | 0.55 |
| ▸ | KDM5C | P41229 | 2/20 | 0.55 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.55 |
| ▸ | PLAT | P00750 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16050360 | 0.91 | KDM5A (0.46) | KDM5AKDM5BKDM5CKDM4C | |
| SCHEMBL17547819 | 0.90 | KDM5A (0.45) | KDM5AKDM5BKDM5CKDM4C | |
| SCHEMBL16092351 | 0.90 | KDM5B (0.49) | KDM5AKDM5BKDM5CKDM4C | |
| SCHEMBL17547867 | 0.89 | KDM5A (0.46) | KDM5AKDM5BKDM5CKDM4C | |
| SCHEMBL16052547 | 0.88 | KDM5A (0.44) | KDM5AKDM5BKDM5CKDM4C | |
| SCHEMBL16050579 | 0.87 | KDM5A (0.45) | KDM5AKDM5BKDM5CKDM4C | |
| SCHEMBL17547865 | 0.87 | KDM5B (0.50) | KDM5AKDM5BKDM5CKDM4C | |
| SCHEMBL16092277 | 0.87 | KDM5A (0.43) | KDM5AKDM5BKDM5CKDM4C | |
| SCHEMBL17080301 | 0.86 | KDM5A (0.42) | KDM5AKDM5BKDM5CKDM4C | |
| SCHEMBL16092253 | 0.86 | KDM5A (0.53) | KDM5AKDM5BKDM5CKDM4CPLAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4072546-B1 | INHIBITORS OF KDM5A FOR USE IN TREATMENT OF IDIOPATHIC INFLAMMATORY MYOPATHIES | UNIV ANTWERPEN (BE) | 2025-02-19 | — | — | EP | claimed |
| US-20230038503-A1 | INHIBITORS OF KDM5A FOR USE IN TREATMENT OF IDIOPATHIC INFLAMMATORY MYOPATHIES | UNIVERSITEIT ANTWERPEN (BE) | 2023-02-09 | — | — | US | claimed |
| EP-4072546-A1 | INHIBITORS OF KDM5A FOR USE IN TREATMENT OF IDIOPATHIC INFLAMMATORY MYOPATHIES | Universiteit Antwerpen (BE) | 2022-10-19 | — | — | EP | claimed |
| WO-2021116372-A1 | INHIBITORS OF KDM5A FOR USE IN TREATMENT OF IDIOPATHIC INFLAMMATORY MYOPATHIES | UNIVERSITEIT ANTWERPEN (BE) | 2021-06-17 | — | — | WO | claimed |
| EP-4058604-B1 | COMPOSITIONS AND METHODS FOR REGULATING EGFR AMPLIFICATION IN CANCER CELLS FOR IMPROVING EGFR-TARGETED ANTI-CANCER AGENT | INSTITUTE FOR CANCER RES (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4615431-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2025-09-17 | — | — | EP | disclosed |
| EP-4072546-B1 | INHIBITORS OF KDM5A FOR USE IN TREATMENT OF IDIOPATHIC INFLAMMATORY MYOPATHIES | UNIV ANTWERPEN (BE) | 2025-02-19 | — | — | EP | disclosed |
| WO-2024100236-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2024-05-16 | — | — | WO | disclosed |
| US-20240139197-A1 | INHIBITION OF KDM5A FOR PROMOTING ANTIGEN PRESENTATION, INCREASING CD8+ T CELL INFILTRATION AND BOOSTING ANTI-TUMOR IMMUNE RESPONSE | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY | 2024-05-02 | — | — | US | disclosed |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-02-16 | — | — | US | disclosed |
| US-10035801-B2 | Pyrazolo compounds and uses thereof | GENENTECH, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-10035801-B2 | Pyrazolo compounds and uses thereof | GENENTECH, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-20180042905-A1 | METHODS OF TREATING HEPATITIS B VIRUS | GILEAD SCIENCES, INC. | 2018-02-15 | — | — | US | disclosed |
| US-20180042905-A1 | METHODS OF TREATING HEPATITIS B VIRUS | GILEAD SCIENCES, INC. | 2018-02-15 | — | — | US | disclosed |
| US-20160303095-A1 | METHODS OF TREATING HEPATITIS B VIRUS | GILEAD SCIENCES, INC. | 2016-10-20 | — | — | US | disclosed |
| US-20160303095-A1 | METHODS OF TREATING HEPATITIS B VIRUS | GILEAD SCIENCES, INC. | 2016-10-20 | — | — | US | disclosed |
| US-20160060267-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-03-03 | — | — | US | disclosed |
| US-20160060267-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10035801-B2 | Pyrazolo compounds and uses thereof | KDM5A, KDM5C, KDM5B | KDM5A 1/4885KDM5B 3/4885KDM5C 2/4885 |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | KDM5A 3261/4885KDM5B 3369/4885KDM5C 3176/4885 |
| US-20180042905-A1 | METHODS OF TREATING HEPATITIS B VIRUS | KDM1B, KDM5B, KDM5A | KDM5A 3/4885KDM5B 2/4885KDM5C 8/4885 |
| US-20240139197-A1 | INHIBITION OF KDM5A FOR PROMOTING ANTIGEN PRESENTATION, INCREASING CD8+ T CELL INFILTRATION AND BOOSTING ANTI-TUMOR IMMUNE RESPONSE | KDM5A, KDM5B, KDM5C | KDM5A 1/4885KDM5B 2/4885KDM5C 3/4885 |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | CYFIP2, TPX2, ATXN2 | KDM5A 2520/4885KDM5B 1925/4885KDM5C 2105/4885 |
| US-20160303095-A1 | METHODS OF TREATING HEPATITIS B VIRUS | KDM1B, KDM5B, KDM5A | KDM5A 3/4885KDM5B 2/4885KDM5C 8/4885 |
| US-20160060267-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | KDM5A, KDM5C, KDM5B | KDM5A 1/4885KDM5B 3/4885KDM5C 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.